We are OVID

Ovid is different — we first take time to understand our patient communities and weave that knowledge with our scientific insights to develop transformative therapies for patients and their families.

By including health care providers, payors and the rare disease community as part of the larger Ovid team, we believe we can realize meaningful change. This model enables us to courageously confront previously unsolved and unmet medical needs in rare neurological disorders.

Developing BoldMedicine to Transform the Lives of People with Rare Neurological Diseases

ovid

What’s in a name?

Ovid Therapeutics is named for the Roman poet, Publius Ovidius Naso, known for his epic work, Metamorphoses or Books of Transformations.

Here at Ovid, each “Ovidian,” is a catalyst for transformation and change, contributing to a diverse environment that enhances our knowledge and growth. It is the diversity of our people and beliefs that drives our community and fuels our approach to both science and business.

“In the make-up of human beings,
intelligence counts for more than our hands,
and that is our true strength.”

– Ovid, Metamorphoses

Leadership

Jeremy Levin, D.Phil., MB BChir, is chief executive officer and chairman of the board of Ovid Therapeutics. He has over 25 years of experience in the global pharmaceuticals industry, leading companies that develop and commercialize innovative and generic medicines that address compelling medical needs worldwide.

Prior to joining Ovid, Jeremy served as president and CEO of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), one of the world’s largest pharmaceutical companies. Prior to that role, he was a member of the executive committee of Bristol-Myers Squibb (NYSE: BMY) where he had global responsibilities for strategy, alliances and transactions and where he created and lead the String of Pearls strategy. Prior to BMS Jeremy was the global head of strategic alliances at Novartis Pharmaceuticals (NYSE: NVS), where he established and managed multiple collaborations with biotechnology companies and academic centers around the world. Jeremy has served on a number of public and private company boards over the years, and currently serves on the board of directors of The Biotechnology Innovation Origination (BIO), BioCon, Ltd. (BSE: Biocon) and privately-held ZappRx. He holds a B.A. in zoology and an M.A. and D.Phil. in the structure of chromatin from the University of Oxford. He also received an MB BS from the University of Cambridge. Jeremy has practiced internal medicine at university hospitals in England, Switzerland and South Africa.

Jeremy was recognized as one of the 25 most influential individuals in Biotechnology by Fierce Biotechnology and is the recipient of a number of awards including the Kermode Prize from The University of Cambridge for work on novel hypertension drugs; the Albert Einstein Award for Leadership in Life Sciences; and the B’nai B’rith Award for Distinguished Achievement for commitment to improving global health care.

Matthew During, M.D., D.Sc., FACP, FRACP, is founder, director, president and chief scientific officer at Ovid Therapeutics. Matthew is one of the world’s foremost researchers in neurology and genetics and pioneered the use of viral vectors for neurological disorders. He has published over 250 articles in the world’s most prestigious medical journals and is the inventor on over 50 patents and patent applications.

Prior to Ovid, Matthew co-founded several leading biotechnology companies including Neurel Inc., Merlin Pharmaceuticals, Neurologix, Inc. and NightstaRx – and was the principal investigator and FDA sponsor for two pioneering gene therapy studies, including the first and only successful Phase 2 trial of a biological therapy for Parkinson’s disease. Previously, he served for nine years on the faculty of Yale University as a professor of neurosurgery. Subsequently, he served as a professor at Cornell and Ohio State Universities for 10 years. Since 2011, he has served as a visiting professor of translational neuroscience at the University of Oxford. After completing his M.D. and D.Sc. in neuroscience and genetics from the University of Auckland, Matthew completed specialty fellowships at the Massachusetts Institute of Technology, Massachusetts General Hospital, Harvard Medical School and Yale University School of Medicine. He is a fellow of the American College of Physicians, the Royal Australasian College of Physicians and the American Association for the Advancement of Science.

Matthew has won many awards including the American Epilepsy Society Young Investigator of the Year; Roche Translational Neuroscience Award; Johnson and Johnson Focused Giving Award; BMS Neuroscience Award; and Nancy Sirrett and Keith Harrison Awards.

Yaron Werber, M.D., MBA is chief business and financial officer at Ovid Therapeutics, where he is responsible for finance, business development, investor and public relations, operations and IT.

Prior to joining Ovid, Yaron had a 14-year tenure as a biotechnology analyst at marquee Wall Street firms. Yaron was a managing director at Citi Research, and the head of the health care and biotech equity research teams. Previously, Yaron was a senior biotech analyst and vice president at SG Cowen Securities. He began his career in academic research and was also a consultant to several leading health care organizations. Yaron received a B.S. in biology from Tufts University and a combined M.D./MBA from Tufts University School of Medicine.

Through his analyst career, Yaron was highly ranked by the Institutional Investor Magazine survey, and also received recognition by Starmine and the “Best on the Street Survey” by the Wall Street Journal. At Citi Research, Yaron received several awards for distinguished performance.

Amit Rakhit, M.D., MBA is chief medical and portfolio officer at Ovid Therapeutics. He oversees late stage clinical development, clinical operations, medical, marketing, market access and digital health. Amit is particularly interested in patient insights and creating innovative bridges between the biotech industry, health technology and patient community to build better capabilities that meet the needs of patients and their caregivers.

Prior to joining Ovid, he was senior vice president, head of worldwide medical at Biogen, where he oversaw medical activities for marketed and pipeline compounds in disease areas such as multiple sclerosis, neurodegenerative diseases, dementia and hemophilia. Previously, he was a program leader at Biogen where he oversaw the global development for potential new therapies in orphan and rare disorders, such as ALS and spinal muscular atrophy. Prior to this, he was with Bristol-Myers Squibb where he led a global medical team in 27 countries with a cross-therapeutic area portfolio that included cardiovascular, metabolics, oncology, HIV, virology, immunology and neuroscience products. Amit received his M.D. from Tufts University. Additionally, he holds a B.A. in molecular biology from the University of California, Berkeley; an MBA from Columbia University and an MBA from the London Business School.

Amit is a Trustee for the Liberty Science Center in Jersey City, N.J. as well as an advisory member of the Healthcare Board of the Partnership Fund for New York City.

Dirk is a seasoned drug development professional with over 20 years of experience in Regulatory Affairs, Medical Marketing, Clinical Development, Drug Safety, and Compliance. Prior to joining Ovid, he was Vice President, Regulatory Strategy and Policy at Lundbeck USA, with responsibility for all FDA interactions on several marketed Orphan Drugs and all Lundbeck development compounds. Dirk has a MSc in Molecular Biology, obtained his PhD at the Basel Institute for Immunology, and holds a postgraduate degree in Pharmaceutical Medicine from the EUCOR Universities Basel, Strasbourg and Freiburg. He started his career in Global Project Management at Hoffmann-La Roche, where he held positions of increasing responsibility in Product Development and Marketing before being appointed Global Life-cycle Leader for the #2 franchise in Global Business Development and Strategic Marketing at the Roche HQ in Switzerland. Dirk co-founded the biotech start-up 4-Antibody that was recently acquired by Agenus. He is a member of the PhRMA Regulatory Affairs Coordinating Committee (RACC), a member of the Legal, Compliance and Regulatory Advisory Committee for BioNJ, and a member of the International Editorial Board of the Journal of Medical Marketing.

Suzanne Wakamoto has been a manager for 30 years and a human resources leader for over 20. Her diverse background includes start-up, global, multi-site and non-profit organizations. She has been fortunate to work and consult in an eclectic array of industries: arts education, biotechnology, construction, entertainment, manufacturing, retail and software. Since 2008, she served as an independent HR consultant where she partnered with clients to develop more cohesive and compliant HR practices that aligned with their corporate culture and business needs. Some of her former corporate positions include: heading HR for the internationally acclaimed Blue Man Group and director of HR & administration for Cadus Pharmaceutical Corporation. Suzanne sits on the board of directors of NYC SHRM, the New York City chapter of the Society of Human Resources Management and is a founder and current chair of HR-PRO, NYC SHRM’s award winning pro-bono outreach program. She holds a Bachelor’s degree in world arts and culture from UCLA. Ultimately, Suzanne is a person who believes excellence and fun are not mutually exclusive, but rather the partnership that makes us successful every day.

Michael Ciraolo, J.D., Ph.D., is vice president, chief intellectual property counsel at Ovid Therapeutics. He is an intellectual property attorney with significant experience leading and implementing effective IP strategies in the areas of pharmaceuticals and biotechnology.

Prior to joining Ovid, Michael spent nine years at Forest Laboratories creating value through global patent prosecution for pharmaceutical products in all phases of development. He has conducted hundreds of due diligence evaluations related to M&A and in-licensing opportunities and has provided strategic advice related to the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act. Previously, Michael was an associate at Arent Fox PLLC and Baker Botts LLP in New York City. Michael received his B.S. in chemistry from SUNY at Brockport, his Ph.D. in chemistry from Stony Brook University and attended St. John’s University School of Law for his J.D.

Tim Daly is vice president, finance and corporate controller at Ovid Therapeutics. He has more than 17 years of experience in the biotech and pharmaceutical healthcare industries.

Prior to joining Ovid, Tim was vice president of finance at AHM, a leading global provider of technology to healthcare professionals. Previously, Tim served as vice president, controller and chief accounting officer at Enzon Pharmaceuticals. Prior to Enzon, he served in various operation finance roles during his 12-year tenure at ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, most recently as director of finance. Tim holds a B.AS. in accounting from Rider University.

Claude Nicaise, M.D., is head, strategic orphan regulatory affairs at Ovid Therapeutics.  He is a respected executive with over 20 years of significant product development experience, particularly in orphan diseases.

Prior to joining Ovid, Claude was an executive vice president of clinical development and regulatory affairs at Formula Pharmaceuticals, Inc. Before that, he was senior vice president, strategic product development and global regulatory affairs at Alexion Pharmaceuticals, where he managed all regulatory activities and co-managed development programs with the head of R&D and designed, interpreted and filed all programs supporting development in rare diseases. Prior to joining Alexion, Claude served in various positions of increasing responsibility at Bristol-Myers Squibb for 24 years. Claude holds an M.D. from the Université libre de Bruxelles in Belgium.

Claude is the author of more than 60 research articles published in peer-reviewed journals and is a member of several professional medical associations, including the American Society of Clinical Oncology; the European Society for Medical Oncology; the American Society for Microbiology; and the American Society of Hematology.

Raquel has over ten years of experience across a variety of healthcare industry sectors in the US and Europe. Raquel is passionate about working with patients, clinicians, and payers at all stages of product development to address true unmet needs and ensure access.

Prior to joining Ovid, Raquel was Director of Global Market Access at GE Healthcare, based in London. In this role she led a global team responsible for market access and health economics for new product introductions from the company’s imaging technology portfolio across all therapy areas. At GE Healthcare, Raquel focused on demonstrating the value of innovative technology through research, customer partnerships, digital marketing, and sales support.

Prior to GE, Raquel was a member of Medtronic’s EMEA health economics and reimbursement team, based in Switzerland. Before joining industry, she was a neuropsychology specialist at Cogstate, a cognitive science start-up, and Columbia University Medical Center where she led operations for federally funded studies that evaluated the specificity of cognitive testing to diagnose Alzheimer’s Disease among minorities.

Raquel earned her MSc in International Health Policy and Health Economics from the London School of Economics and earned her BA in Psychology and French, cum laude, from the University of Pennsylvania. She is also a member of the University of Pennsylvania Fund executive board.

Jeannie Visootsak, M.D., M.Sc. is board-certified in general pediatrics and developmental-behavioral pediatrics with expertise in clinical-translational research specifically in pediatric and adults neurodevelopmental disorders, genetic conditions and rare diseases.

Prior to joining Ovid, Jeannie was the translational medicine leader at Roche Neuroscience where she led the global Down syndrome adult and pediatric Phase 2a and 2b clinical trials and non-interventional outcome measure studies for the development of Basmisanil (selective GABAA α5 receptor negative allosteric modulator). Prior to joining the pharmaceutical industry, Jeannie was an associate professor at Emory University School of Medicine from 2004 to 2014 and directed the Down syndrome and Fragile X syndrome centers to provide clinical care, research and education. She also provided clinical care for individuals with other developmental disabilities such as autism, genetic conditions and metabolic disorders. She has published more than 40 peer-reviewed manuscripts and book chapters, and served as a primary investigator on more than 15 Phase 1, 2 and 3 neurodevelopmental and rare diseases clinical trials. Jeannie received her M.D. from UCLA School of Medicine and M.Sc. in clinical research at Emory University.

Jeannie has also worked closely with patient advocacy groups. She co-founded the Fragile X Clinical and Research Consortium with the National Fragile X Foundation in 2005 and currently serves on the board of directors and professional advisory committee for the National Down Syndrome Congress. Jeannie has also published children’s books entitled “Fragile X Fred” and “What’s Inside You Is Inside Me, Too: My Chromosomes Make Me Unique.”

Board of Directors

Jeremy Levin, D.Phil., MB BChir, is chief executive officer and chairman of the board of Ovid Therapeutics. He has over 25 years of experience in the global pharmaceuticals industry, leading companies that develop and commercialize innovative and generic medicines that address compelling medical needs worldwide.

Prior to joining Ovid, Jeremy served as president and CEO of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), one of the world’s largest pharmaceutical companies. Prior to that role, he was a member of the executive committee of Bristol-Myers Squibb (NYSE: BMY) where he had global responsibilities for strategy, alliances and transactions and where he created and lead the String of Pearls strategy. Prior to BMS Jeremy was the global head of strategic alliances at Novartis Pharmaceuticals (NYSE: NVS), where he established and managed multiple collaborations with biotechnology companies and academic centers around the world. Jeremy has served on a number of public and private company boards over the years, and currently serves on the board of directors of The Biotechnology Innovation Origination (BIO), BioCon, Ltd. (BSE: Biocon) and privately-held ZappRx. He holds a B.A. in zoology and an M.A. and D.Phil. in the structure of chromatin from the University of Oxford. He also received an MB BS from the University of Cambridge. Jeremy has practiced internal medicine at university hospitals in England, Switzerland and South Africa.

Jeremy was recognized as one of the 25 most influential individuals in Biotechnology by Fierce Biotechnology and is the recipient of a number of awards including the Kermode Prize from The University of Cambridge for work on novel hypertension drugs; the Albert Einstein Award for Leadership in Life Sciences; and the B’nai B’rith Award for Distinguished Achievement for commitment to improving global health care.

Karen Bernstein, Ph.D., is currently Chairman of BioCentury Inc., which she founded in 1987. She has received numerous biotech and medical industry honors for contributions to the field.

Dr. Bernstein holds a board membership at Ovid Therapeutics (since September 2015) and was on the board of Vitae Pharmaceuticals (from September 2015 through its acquisition by Allergan in October 2016).  She is a Trustee at the Keck Graduate Institute and a member of the board of advisors of the KGI School of Pharmacy. Previously, she served on the Brandeis University Science Advisory Council.

Dr. Bernstein received a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University.

Matthew During, M.D., D.Sc., FACP, FRACP, is founder, director, president and chief scientific officer at Ovid Therapeutics. Matthew is one of the world’s foremost researchers in neurology and genetics and pioneered the use of viral vectors for neurological disorders. He has published over 250 articles in the world’s most prestigious medical journals and is the inventor on over 50 patents and patent applications.

Prior to Ovid, Matthew co-founded several leading biotechnology companies including Neurel Inc., Merlin Pharmaceuticals, Neurologix, Inc. and NightstaRx – and was the principal investigator and FDA sponsor for two pioneering gene therapy studies, including the first and only successful Phase 2 trial of a biological therapy for Parkinson’s disease. Previously, he served for nine years on the faculty of Yale University as a professor of neurosurgery. Subsequently, he served as a professor at Cornell and Ohio State Universities for 10 years. Since 2011, he has served as a visiting professor of translational neuroscience at the University of Oxford. After completing his M.D. and D.Sc. in neuroscience and genetics from the University of Auckland, Matthew completed specialty fellowships at the Massachusetts Institute of Technology, Massachusetts General Hospital, Harvard Medical School and Yale University School of Medicine. He is a fellow of the American College of Physicians, the Royal Australasian College of Physicians and the American Association for the Advancement of Science.

Matthew has won many awards including the American Epilepsy Society Young Investigator of the Year; Roche Translational Neuroscience Award; Johnson and Johnson Focused Giving Award; BMS Neuroscience Award; and Nancy Sirrett and Keith Harrison Awards.

Bart Friedman, J.D. has been a partner at the Wall Street law firm Cahill Gordon & Reindel LLP since 1970 and chairs its business development committee. Bart advises leading financial institutions and global corporations, boards of directors, audit committees, officers and directors of publicly-held companies on significant corporate and securities matters, both in the U.S. and abroad. Bart received his J.D. from Harvard Law School in 1969, and spent a year on the research faculty of the Harvard Business School, and joined Cahill immediately thereafter. He took a brief leave from his legal career to serve at the Securities and Exchange Commission and returned to Cahill in 1977.

Douglas E. Williams, Ph.D., is currently the president, CEO and member of the board of directors of Codiak BioSciences, and was previously Biogen’s executive vice president, research and development having served in this position from January 2011 to July 2015.  He joined Biogen from ZymoGenetics Inc., where he was most recently CEO and member of the board of directors. ZymoGenetics was purchased for $985 million by Bristol Myers Squibb during Dr Williams’ tenure.  Previously, he held leadership positions within the biotechnology industry, including chief scientific officer and executive vice president of research and development at Seattle Genetics Inc., and senior vice president and Washington site leader at Amgen Inc. Dr. Williams also served in a series of scientific and senior leadership positions over a decade at Immunex Corp., including executive vice president and chief technology officer and a member of the board of directors.  He has served on the board of numerous biotechnology companies and is currently a member of the board of directors for Ironwood Pharmaceuticals, Ovid Pharmaceuticals and Regulus Pharmaceuticals.

Scientific Advisory Board

Howard Federoff, M.D., Ph.D., is the chairman of the scientific advisory board for Ovid Therapeutics. He is also vice chancellor for health affairs and dean of the School of Medicine at the University of California at Irvine, where he has oversight of the clinical, medical educational and research missions. Prior to UCI, Howard was the executive vice president for health sciences at Georgetown University and executive dean of the School of Medicine, where he was a professor of neurology. Prior to Georgetown, he held appointments as senior associate dean; professor of neurology, medicine, microbiology and immunology; professor of oncology and genetics at the University of Rochester School of Medicine; founding director of the Center for Aging and Development Biology at the Aab Institute of Biomedical Sciences; and founding division chief of molecular medicine and gene therapy. His research interests include gene therapy and neurodegenerative diseases. He has published more than 250 peer-reviewed and invited articles and serves as a reviewer for many journals as well as on the editorial board of five journals. Howard served as chair of the NIH Recombinant DNA Advisory Committee from 2007-2010. He chairs the Gene Therapy Resource Program for NHLBI, was president of the American Society for Neural Therapy and Repair from 2013 to 2013 and is president of the American Society for Experimental Neurotherapeutics. Dr. Federoff received his M.S., Ph.D. and M.D. degrees from the Albert Einstein College of Medicine, did his internship, residency and clinical and research fellowships at Massachusetts General Hospital (MGH)/Harvard Medical School, and practiced medicine at MGH, Albert Einstein and Strong Memorial Hospital at the University of Rochester. He is a Fellow of the AAAS and National Academy of Inventors.

Matthew During, M.D., D.Sc., FACP, FRACP, is founder, director, president and chief scientific officer at Ovid Therapeutics. Matthew is one of the world’s foremost researchers in neurology and genetics and pioneered the use of viral vectors for neurological disorders. He has published over 250 articles in the world’s most prestigious medical journals and is the inventor on over 50 patents and patent applications.

Prior to Ovid, Matthew co-founded several leading biotechnology companies including Neurel Inc., Merlin Pharmaceuticals, Neurologix, Inc. and NightstaRx – and was the principal investigator and FDA sponsor for two pioneering gene therapy studies, including the first and only successful Phase 2 trial of a biological therapy for Parkinson’s disease. Previously, he served for nine years on the faculty of Yale University as a professor of neurosurgery. Subsequently, he served as a professor at Cornell and Ohio State Universities for 10 years. Since 2011, he has served as a visiting professor of translational neuroscience at the University of Oxford. After completing his M.D. and D.Sc. in neuroscience and genetics from the University of Auckland, Matthew completed specialty fellowships at the Massachusetts Institute of Technology, Massachusetts General Hospital, Harvard Medical School and Yale University School of Medicine. He is a fellow of the American College of Physicians, the Royal Australasian College of Physicians and the American Association for the Advancement of Science.

Matthew has won many awards including the American Epilepsy Society Young Investigator of the Year; Roche Translational Neuroscience Award; Johnson and Johnson Focused Giving Award; BMS Neuroscience Award; and Nancy Sirrett and Keith Harrison Awards.

David Eidelberg, M.D. is internationally recognized for his pioneering work using functional brain networks as biomarkers of neurological disease. Using PET and fMRI, he and his colleagues have identified and validated specific network biomarkers for Parkinson’s disease, Huntington’s disease, dystonia and Tourette syndrome, as well as cognitive disorders such as Alzheimer’s disease and fronto-temporal dementia. His work has led to accurate network-based algorithms for early diagnosis and assessment of disease progression in individuals with these disorders.

Dr. Eidelberg received his medical degree from Harvard Medical School. After completing residency training in neurology at Harvard, he pursued postdoctoral training in brain imaging with MRI (National Hospital, London) and PET (Cornell, New York). He has led the Center for Neurosciences at The Feinstein Institute for Medical Research since its founding in 2001, serving as director and Susan and Leonard Feinstein professor of neurology and neuroscience. Since 1995, Dr. Eidelberg has received over $15 million in research support from the NIH and other prominent funding agencies. He is the author of over 350 peer-reviewed research articles, editorials and reviews, as well as a textbook (Brain Imaging in Parkinson’s Disease, Oxford University Press 2011). He serves on the editorial boards of several high-impact journals in the neurology, neuroscience and brain imaging space, and is a scientific advisor to the Michael J. Fox Foundation, the Department of Defense, and the COBRE Center for Neurodegeneration and Translational Neuroscience (CNTN).

Jacqueline A. French, M.D., is a professor in the department of neurology, director of translational research & clinical trials in epilepsy and a neurologist at the Comprehensive Epilepsy Center at the New York University (NYU) Langone Medical Center. She is also a founder and director of the Clinical Trials Consortium, an academic group that has performed a number of early-phase clinical trials in epilepsy, and she currently serves as chief scientific officer of the Epilepsy Foundation. Previously, Dr. French chaired an American Academy of Neurology (AAN)/American Epilepsy Society (AES) committee that developed two guidelines on the use of new antiepileptic drugs and has helped create guidelines for the International League Against Epilepsy. Dr. French was also president and served on the board of the AES and was the secretary of the American Society of Experimental Neurotherapeutics. She has authored more than 200 articles and chapters, is the editor of three books, and lectures internationally on clinical trials and the use of antiepileptic drugs. She was the 2005 recipient of the AES Service Award and the 2013 Epilepsy Foundation Hero award. Dr. French received a medical degree from Brown University. She completed her residency in neurology at Mount Sinai Hospital in New York and completed fellowships in epilepsy at Mount Sinai Hospital and Yale University.

Dr. Daniel Geschwind is the Gordon and Virginia MacDonald Distinguished Professor of neurology, psychiatry and human genetics at the UCLA School of Medicine. He is director of the Neurogenetics Program and the Center for Autism Research and Treatment (CART) and co-director of the Center for Neurobehavioral Genetics in the Semel Institute at UCLA. Dr. Geschwind is also the senior associate dean and associate vice chancellor of precision medicine in the UCLA Health System and David Geffen School of Medicine. His laboratory aims to develop a mechanistic understanding of neuropsychiatric diseases, namely autism and neurodegenerative diseases, and their relationship to the range of normal human higher cognitive function and behavior. The lab’s approach relies heavily on computational and bioinformatic methods in addition to wet laboratory experimentation. The ultimate goal is to use these integrative approaches to help develop effective therapeutics for neurologic and psychiatric disorders, focusing on autism and neurodegenerative disorders.

Dr. Geschwind is also a strong advocate for data and biomaterial sharing, having provided scientific oversight for the Autism Genetic Resource Exchange (AGRE). He has served on numerous scientific advisory boards, including the Faculty of 1000 Medicine; the executive committee of the American Neurological Association; the NIMH Advisory Council; and the NIH Council of Councils. He has published over 300 papers and serves on the editorial boards of Biological Psychiatry; Cell; Current Opinion in Genetics & Development; Human Molecular Genetics; Neurobiology of Disease; and Neuron and Science. He received the Derek Denny-Brown Neurological Scholar Award from the American Neurological Association in 2004; the Scientific Service Award from Autism Speaks in 2007; the Ruane Prize for Child and Adolescent Psychiatric Research from the Brain and Behavior foundation in 2012; the Taking on Tomorrow Innovation Award (Research/Scientific Breakthrough in Autism) -Boston Children’s Hospital in 2013; and is an elected member of the Institute of Medicine of the National Academies, USA.

Jerome B. Zeldis, M.D., Ph.D., is chief medical officer and president of clinical development at Sorrento Therapeutics. Prior to this role, Dr. Zeldis was chief executive officer of Celgene Global Health. Previously, he was chief medical officer and senior vice president of clinical research and medical affairs at Celgene Corporation and had been at Celgene since February 1997. He attended Brown University for an A.B., M.S., followed by Yale University for an M.Phil., M.D., Ph.D. in molecular biophysics and biochemistry (immunochemistry). Dr. Zeldis trained in internal medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was assistant professor of medicine at the Harvard Medical School, associate professor of medicine at University of California, Davis, clinical associate professor of medicine at Cornell Medical School and professor of clinical medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Prior to working at Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He has been a board member of a few start-up biotechnology companies and is currently on the board of the Semorex Corporation, PTC Corporation, Soligenix, Trek Therapeutics and BionorPharma. He has published 122 peer reviewed articles and 24 reviews, book chapters and editorials.